Ocugen Inc

Ocugen Inc., a biotechnology company, saw its stock price surge 460% after investors reacted to its imminent earnings release, driven by optimism over its gene-therapy pipeline and ambitious plans for regulatory approvals.

Ocugen, Inc., a biopharmaceutical company focused on regenerative medicine and joint health, faces significant financial challenges, including a negative Price Earnings ratio and volatile stock price, raising concerns about its stability and ability…

Ocugen, Inc., a clinical-stage biopharmaceutical company, is making significant strides in the biotechnology industry with a focus on regenerative medicine and innovative products aimed at improving joint function and preventing degenerative disease…

Ocugen Inc. reported a 20% increase in revenue to $1.4 million in Q2 2025, beating expectations and marking a strong performance for the clinical-stage biopharmaceutical company.

Ocugen Inc. reported a GAAP EPS of -$0.05 and $1.48 million in revenue for its first quarter 2025, exceeding earnings expectations despite a decline in revenue compared to the previous year.